Advertisement

Pityriasis Lichenoides Acuta

  • Andrea Andreassi
  • Lucio AndreassiEmail author

Abstract

Pityriasis lichenoides et varioliformis acuta (PLEVA), or acute guttate parapsoriasis, or Mucha-Habermann disease, is the acute form of a papulosquamous cutaneous disorder, whose chronic form is also known as pityriasis lichenoides chronica (PLC) or chronic guttate parapsoriasis. In cases with fever, an antibiotic treatment is always useful. In children, erythromycin is the antibiotic of choice, whereas tetracycline is preferable in adults. In cases without fever with moderate cutaneous lesions, in addition to topical treatment with steroid creams, it may be appropriate to start phototherapy.

References

  1. Aydogan K, Saricaoglu H, Turan H. Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides. Photodermatol Photoimmunol Photomed. 2008;24:128–33.CrossRefGoogle Scholar
  2. Ersoy-Evans S, Greco MF, Mancini AJ, Subaşi N, Paller AS. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol. 2007;56:205–10.CrossRefGoogle Scholar
  3. Farnaghi F, Seirafi H, Ehsani AH, Agdari ME, Noormohammadpour P. Comparison of the therapeutic effects of narrow band UVB vs. PUVA in patients with pityriasis lichenoides. J Eur Acad Dermatol Venereol. 2011;25:913–6.CrossRefGoogle Scholar
  4. Hapa A, Ersoy-Evans S, Karaduman A. Childhood pityriasis lichenoides and oral erythromycin. Pediatr Dermatol. 2012;29:719–24.CrossRefGoogle Scholar
  5. Pinton PC, Capezzera R, Zane C, De Panfilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol. 2002;47:410–4.CrossRefGoogle Scholar
  6. Romani J, Puig L, Fernandez-Figueras MT, de Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol. 1998;15:1–6.CrossRefGoogle Scholar
  7. Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol. 1986;15:66–70.CrossRefGoogle Scholar

Further Reading

  1. Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol. 2006;55:557–72.CrossRefGoogle Scholar
  2. Cornelison Jr RL, Knox JM, Everett MA. Methotrexate for the treatment of Mucha-Habermann disease. Arch Dermatol. 1972;106:507–8.CrossRefGoogle Scholar
  3. Fernandes NF, Rozdeba PJ, Schwartz RA, Kihiczak G, Lambert WC. Pityriasis lichenoides et varioliformis acuta: a disease spectrum. Int J Dermatol. 2010;49:257–61.CrossRefGoogle Scholar
  4. Ito N, Ohshima A, Hashizume H, Takigawa M, Tokura Y. Febrile ulceronecrotic Mucha-Habermann’s disease managed with methylprednisolone semipulse and subsequent methotrexate therapies. J Am Acad Dermatol. 2003;49:1142–8.CrossRefGoogle Scholar
  5. Kaufman WS, McNamara EK, Curtis AR, et al. Febrile ulceronecrotic Mucha-Habermann disease (pityriasis lichenoides et varioliformis acuta fulminans) presenting as Stevens-Johnson syndrome. Pediatr Dermatol. 2012;29:135–40.CrossRefGoogle Scholar
  6. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024–35.CrossRefGoogle Scholar
  7. Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol. 2012;36:1021–9.CrossRefGoogle Scholar
  8. Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29–36.CrossRefGoogle Scholar
  9. Kim HS, Yu DS, Kim JW. A case of febrile ulceronecrotic Mucha-Habermann’s disease successfully treated with oral cyclosporin. J Eur Acad Dermatol Venereol. 2007;21:272–3.PubMedGoogle Scholar
  10. Macias VC, Marques-Pinto G, Cardoso J. Phototherapy for pityriasis lichenoides: our experience. Cutan Ocul Toxicol. 2013;32:124–7.CrossRefGoogle Scholar
  11. Marenco F, Fava P, Fierro MT, Quaglino P, Bernengo MG. High-dose immunoglobulins and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. Dermatol Ther. 2010;23:419–22.CrossRefGoogle Scholar
  12. Miyamoto T, Takayama N, Kitada S, Hagari Y, Mihara M. Febrile ulceronecrotic Mucha-Habermann disease: a case report and a review of the literature. J Clin Pathol. 2003;56:795–7.CrossRefGoogle Scholar
  13. Muhlbauer JE, Bhan AK, Harrist TJ, et al. Immunopathology of pityriasis lichenoides acuta. J Am Acad Dermatol. 1984;10:783–95.CrossRefGoogle Scholar
  14. Nassif PW, Godoy DA, Nakandakari S, Alves CJ, Soares CT. Febrile ulceronecrotic Mucha-Habermann disease in adult patient successfully treated with systemic corticosteroid. An Bras Dermatol. 2010;85:891–4.CrossRefGoogle Scholar
  15. Perrin BS, Yan AC, Treat JR. Febrile ulceronecrotic Mucha-Habermann disease in a 34-month-old boy: a case report and review of the literature. Pediatr Dermatol. 2012;29:53–8.CrossRefGoogle Scholar
  16. Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. 1974;91:319–22.CrossRefGoogle Scholar
  17. Simon D, Boudny C, Nievergelt H, Simon HU, Braathen LR. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol. 2004;150:1033–5.CrossRefGoogle Scholar
  18. Sotiriou E, Patsatsi A, Tsorova C, Lazaridou E, Sotiriadis D. Febrile ulceronecrotic Mucha-Habermann disease: a case report and review of the literature. Acta Derm Venereol. 2008;88:350–5.PubMedGoogle Scholar
  19. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13:406–9.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of SienaSienaItaly

Personalised recommendations